13.08
3.15%
0.40
Pre-market:
13.20
0.12
+0.92%
Arcutis Biotherapeutics Inc stock is traded at $13.08, with a volume of 1.45M.
It is up +3.15% in the last 24 hours and down -12.74% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$12.68
Open:
$12.78
24h Volume:
1.45M
Relative Volume:
0.72
Market Cap:
$1.53B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.3367
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-1.51%
1M Performance:
-12.74%
6M Performance:
+34.15%
1Y Performance:
+302.46%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.08 | 1.53B | 59.61M | -262.14M | -247.49M | -3.92 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Aug-28-24 | Initiated | Jefferies | Buy |
Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
Sep-07-22 | Initiated | Needham | Buy |
Mar-17-22 | Initiated | Goldman | Buy |
Jun-30-21 | Initiated | Mizuho | Buy |
May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
Oct-08-20 | Initiated | Truist | Buy |
Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
Feb-25-20 | Initiated | Cowen | Outperform |
Feb-25-20 | Initiated | Goldman | Neutral |
Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Objective long/short (ARQT) Report - Stock Traders Daily
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3% - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4%Time to Sell? - MarketBeat
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - Yahoo Finance
Arcutis Biotherapeutics’ (ARQT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Arcutis stock target lifted, buy rating held on significant developments By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap UpStill a Buy? - MarketBeat
Arcutis stock target lifted, buy rating held on significant developments - Investing.com India
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews - Benzinga
JPMorgan Chase & Co. Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Shares Climb on Strong Product Revenue Estimates - MarketWatch
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024 - Marketscreener.com
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - The Manila Times
Arcutis Q4 Revenue Surges 366% to $63M as ZORYVE Demand Accelerates Across Indications - StockTitan
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer -June 01, 2021 at 07:30 am EDT - Marketscreener.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Here's What Happened - MarketBeat
Commit To Purchase Arcutis Biotherapeutics At $7.50, Earn 21.3% Using Options - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says - Defense World
When the Price of (ARQT) Talks, People Listen - Stock Traders Daily
Mizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week HighHere's What Happened - MarketBeat
Arcutis stock soars to 52-week high, hits $15.85 amid robust gains - Investing.com
Mizuho lifts Arcutis stock price target to $20, maintains Outperform By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director Welgus sells $146,714 in stock By Investing.com - Investing.com Nigeria
Mizuho lifts Arcutis stock price target to $20, maintains Outperform - Investing.com
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat
Arcutis Biotherapeutics director Welgus sells $146,714 in stock - Investing.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Grants 75,500 RSUs to New Hires in Strategic Talent Acquisition Move - StockTitan
Here's Why Arcutis Stock More Than Doubled In Market Value In One Year - Barchart
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 7% HigherHere's Why - MarketBeat
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - Simply Wall St
What is HC Wainwright’s Forecast for ARQT FY2024 Earnings? - Defense World
FY2024 Earnings Estimate for ARQT Issued By HC Wainwright - MarketBeat
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 1,691 Shares - MarketBeat
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 - Investing.com India
Looking Ahead to 2025 Dermatology Drug Approvals - Dermatology Times
H.C. Wainwright initiates Buy on Arcutis Biotherapeutics shares highlighting Zoryve potential - Investing.com Canada
HC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):